OCT 20·SEC EDGARLow
Altman Peter purchased $475 of BCDA
Altman Peter (President and CEO) purchased 500 shares of BioCardia, Inc. (BCDA) at $0.95 across 2 trades over 2026-10-15 to 2026-10-16.
StockNASDAQ · US · USDHealthcare · Biotechnology
$BCDA
BioCardia, Inc.
Price · $BCDAvia TradingView
AI sentiment · 7d6 articles
- Bullish
- 6
- Neutral
- 0
- Bearish
- 0
Insider · 30dAll trades →
- Buys
- $4K 4 txs
- Sells
- — 0 txs
Altman Peter4× · $4K
10b5-1 share of filings0%
Top stories · $BCDAMore →
OCT 19·tradingview.com
BioCardia: FDA Accepts De Novo Pre-Submission for Helix Catheter; Substantive Review, Meeting Expected This Quarter
BioCardia's FDA pre-submission for Helix catheter was accepted, with substantive review and a meeting expected this quarter. The FDA raised no concerns about safety or performance. The company has clinical data from 15 trials supporting potential clearance, which could expand partnerships. According to the company, marketing clearance could enhance opportunities with cardiac biologics developers.
OCT 19·SEC EDGAR 8-K
BioCardia Announces FDA Acceptance of De Novo Pre-Submission Package for HelixTM Catheter Marketing Clearance FDA Substantive Review and Meeting Expected…
BioCardia, Inc. (BCDA) filed an SEC Form 8-K — Other Events. Exhibit 99.1 BioCardia Announces FDA Acceptance of De Novo Pre-Submission Package for Helix TM Catheter Marketing Clearance FDA Substantive Review and Meeting Expected this Quarter October 19, 2026, Sunnyvale, Calif. BioCardia, Inc. [NASDAQ: BCDA] , a global leader in cellular an
BCDA sentiment & insider activity
Over the past 7 days, AlphAI's AI scored 6 news stories mentioning BCDA (BioCardia, Inc.). Coverage has skewed bullish: 6 bullish, 0 neutral, and 0 bearish.
Recent BCDA coverage spans regulation, insider activity and financial news.
In the last 30 days, BCDA insiders filed 4 SEC Form 4 transactions — 4 purchases ($4K) and no sales. The most active reporter was Altman Peter, President and CEO, with 4 filings.
What's driving BCDA
The insider purchase signals confidence but the amount is small relative to total shares.
Positive regulatory progress likely lifts sentiment and may drive short‑term upside.
Positive regulatory momentum expected to lift the stock as investors price in potential FDA clearance.
Potential FDA approval could boost valuation.
The disclosure highlights progress toward FDA approval, which may lift sentiment.
AlphAI scores every news story that mentions BCDA with an AI model for sentiment and relevance, and aggregates insider trades from BioCardia, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
News on $BCDA
Score
Altman Peter purchased $475 of BCDA
Altman Peter (President and CEO) purchased 500 shares of BioCardia, Inc. (BCDA) at $0.95 across 2 trades over 2026-10-15 to 2026-10-16.
1 min read
BioCardia: FDA Accepts De Novo Pre-Submission for Helix Catheter; Substantive Review, Meeting Expected This Quarter
BioCardia's FDA pre-submission for Helix catheter was accepted, with substantive review and a meeting expected this quarter. The FDA raised no concerns about safety or performance. The company has clinical data from 15 trials supporting potential clearance, which could expand partnerships. According to the company, marketing clearance could enhance opportunities with cardiac biologics developers.
1 min readBioCardia Announces FDA Acceptance of De Novo Pre-Submission Package for HelixTM Catheter Marketing Clearance FDA Substantive Review and Meeting Expected…
BioCardia, Inc. (BCDA) filed an SEC Form 8-K — Other Events. Exhibit 99.1 BioCardia Announces FDA Acceptance of De Novo Pre-Submission Package for Helix TM Catheter Marketing Clearance FDA Substantive Review and Meeting Expected this Quarter October 19, 2026, Sunnyvale, Calif. BioCardia, Inc. [NASDAQ: BCDA] , a global leader in cellular an
2 min readBioCardia presents CardiAMP HF II trial design at HFSA, FDA signals trial may support approval
BioCardia presented the CardiAMP HF II trial design at HFSA, aiming to test cell therapy in heart failure patients. The FDA agreed the trial may support approval. The company will post materials and meet experts at the meeting. According to the company, the FDA granted category B designation for CardiAMP.
1 min readBioCardia Presents CardiAMP HF II Trial Design at Heart Failure Society of America Annual Scientific Meeting
BioCardia, Inc. (BCDA) filed an SEC Form 8-K — Other Events. Exhibit 99.1 BioCardia Presents CardiAMP HF II Trial Design at Heart Failure Society of America Annual Scientific Meeting SUNNYVALE, Calif. – October 7, 2026 – BioCardia, Inc. [Nasdaq: BCDA], a global leader in cellular and cell-derived therapeutics for the treatment of cardiovas
1 min readBioCardia Files Revised De Novo Pre-Submission for FDA Approval of Helix™ Catheter
BioCardia, Inc. (BCDA) filed an SEC Form 8-K — Other Events. Exhibit 99.1 BioCardia Files Revised De Novo Pre-Submission for FDA Approval of Helix ™ Catheter SUNNYVALE, Calif. – October 1, 2026 – BioCardia, Inc. [Nasdaq: BCDA], a global leader in cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary disea
2 min readBioCardia Files Revised De Novo Pre-Submission for FDA Approval of Helix™ Catheter
BioCardia (BCDA) submitted a revised pre-submission to the FDA for approval of its Helix Catheter, following FDA feedback. The FDA previously agreed on two pathways for marketing clearance and had no concerns about safety data or device performance. FDA aims to review the submission within 15 days and provide feedback within 70 days. Approval could expand BioCardia's partnership opportunities for targeted heart delivery of therapeutics.
2 min readAltman Peter purchased $1K of BCDA
Altman Peter (President and CEO) purchased 1,000 shares of BioCardia, Inc. (BCDA) at $1.03 on 2026-09-29.
1 min readAltman Peter purchased $2K of BCDA
Altman Peter (President and CEO) purchased 1,900 shares of BioCardia, Inc. (BCDA) at $1.05 on 2026-09-23.
1 min readBioCardia Confirms Timing and Provides Update on FDA Helix Pre-Submission and PMDA CardiAMP HF Shonin Submission
BioCardia, Inc. (BCDA) filed an SEC Form 8-K — Other Events. Exhibit 99.1 BioCardia Confirms Timing and Provides Update on FDA Helix Pre-Submission and PMDA CardiAMP HF Shonin Submission SUNNYVALE, Calif. – September 23, 2026 – BioCardia, Inc. [Nasdaq: BCDA], a global leader in cellular and cell-derived therapeutics for the treatment of ca
2 min read